Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096743 | 1.00 | CCR5 (0.40) | CCR5CCR3OPRM1OPRL1SLC18A3 | |
| SCHEMBL8312834 | 1.00 | CCR5 (0.40) | CCR5CCR3OPRM1OPRL1SLC18A3 | |
| SCHEMBL6098489 | 0.85 | DRD4 (0.36) | CCR3OPRM1OPRL1DRD4CCR1 | |
| SCHEMBL6098492 | 0.85 | DRD4 (0.36) | CCR3OPRM1OPRL1DRD4CCR1 | |
| SCHEMBL8306421 | 0.85 | DRD4 (0.36) | CCR3OPRM1OPRL1DRD4CCR1 | |
| SCHEMBL6273496 | 0.84 | CXCR3 (0.39) | CCR5CCR3TP53MDM2 | |
| SCHEMBL6095983 | 0.80 | CXCR3 (0.42) | CCR5TP53MDM2SMN1; SMN2CCR1 | |
| SCHEMBL6097442 | 0.80 | CXCR3 (0.42) | CCR5TP53MDM2SMN1; SMN2CCR1 | |
| SCHEMBL6094896 | 0.75 | DRD4 (0.41) | DRD4 | |
| SCHEMBL6094902 | 0.75 | DRD4 (0.41) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605941-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | claimed |
| US-6916833-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | claimed |
| WO-2004080460-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | claimed |
| US-7060713-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1605941-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20050171157-A1 | 3-alkyl- or alkenyloxy-4-phenyl-4-phenylalkoxypiperidines that may be N-substituted, e.g., cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine; treating breast or colon cancer | KIM KYUNGJIN (US) | 2005-08-04 | — | — | US | disclosed |
| US-6916833-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| WO-2004080460-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171157-A1 | 3-alkyl- or alkenyloxy-4-phenyl-4-phenylalkoxypiperidines that may be N-substituted, e.g., cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine; treating breast or colon cancer | KRAS, TMEM205, ABCB11 | CCR5 324/4885CCR3 301/4885OPRM1 1014/4885 |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | PSMB1, UBQLN1, UBE2N | CCR5 3871/4885CCR3 3548/4885OPRM1 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.